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circulation within the population, 
and economies can and will recover 
quickly once the virus is greatly 
reduced or eliminated. China and 
Australia have shown this is possible. 
In contrast, the economic costs 
of lockdowns increase with their 
duration.1 
Third, the control of the spread 
is most effective at low case 
numbers. Easing restrictions while 
accepting higher case numbers is 
a short-sighted strategy that will 
lead to another wave, and thus to 
higher costs for society as a whole. 
Testing and tracing capacities are 
limited: only with sufficiently low 
case numbers can the test–trace–
isolate–support strategy quickly and 
efficiently help mitigate the spread.2,3 
Hence, milder and more targeted 
physical distancing measures are 
sufficient, and schools and businesses 
can stay open.
Fourth, contact tracing and 
quarantine is not feasible at high 
infection prevalence. Assuming a state 
with 300 new cases per million per 
day, ten contacts per case, and 10 days 
quarantine: then 3% of the population 
would need to be in quarantine, 
resulting in strong reductions of the 
workforce.
Fifth, aiming for naturally acquired 
population immunity is not an 
option.4 The heavy burden in terms of 
morbidity and mortality, reflected also 
in the current excess mortality, and 
the uncertain duration of immunity 
should strongly discourage this 
approach.
Sixth, planning is possible. When 
case numbers are low, there is no 
need for rapid policy changes. This 
reduces the economic damage and 
the uncertainty and strain on mental 
health. However, if case numbers 
rise too high, preventive measures 
must be taken decisively to bring 
them down again—and the earlier, 
the better.5–7 To better manage the 
COVID-19 pandemic, we propose a 
strategy with three core elements 
(panel).
Calling for pan-European 
commitment for rapid 
and sustained reduction 
in SARS-CoV-2 infections
Across Europe, the COVID-19 
pandemic is causing excess deaths, 
placing a burden on societies and 
health systems and harming the 
economy. European governments 
have yet to develop a common vision 
to guide the management of the 
pandemic. Overwhelming evidence 
shows that not only public health, 
but also society and the economy 
benefit greatly from reducing cases 
of severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) infection. 
Vaccines will help control the virus, but 
not until late 2021. 
If European governments do not act 
now, further waves of infection are 
to be expected, with consequential 
damage to health, society, jobs, 
and businesses. With open borders 
across Europe, a single country 
alone cannot keep the number of 
COVID-19 cases low; joint action and 
common goals among countries are 
therefore essential. We therefore call 
for a strong, coordinated European 
response and clearly defined goals for 
the medium and long term. Achieving 
and maintaining low case numbers 
should be the common, pan-European 
goal for the following reasons. 
First, low case numbers save lives, 
and fewer people will die or suffer 
from long-term effects of COVID-19. 
In addition, medical resources will 
not be diverted from other patients in 
need. 
Second, low case numbers save 
jobs and businesses. The economic 
impact of COVID-19 is driven by viral 
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Panel: A joint European strategy for the COVID-19 pandemic
1 Achieve low case numbers
(i) Aim for a target of no more than ten new COVID-19 cases per million people per 
day. This target has been reached in many countries, and can be reached again 
throughout Europe by spring, 2021, at the latest.
(ii) Take firm action to reduce case numbers quickly. Strong interventions have 
proven efficient and balance the rapid achievement of low case numbers against 
the strain on mental health and the economy.
(iii) To avoid a ping-pong effect of importing and reimporting severe acute 
respiratory syndrome coronavirus 2 infections, the reduction should be 
synchronised across all European countries and start as soon as possible. This 
synchronisation will allow European borders to stay open.
2 Keep case numbers low
(i) When case numbers are low, easing of restrictions is possible but should be 
carefully monitored. Continue and improve targeted mitigation measures, such 
as mask wearing, hygiene, moderate contact reduction, testing, and contact 
tracing.
(ii) Even if case numbers are low, a strategy for surveillance testing (at the very least 
300 tests per million people per day) should be in place so that an increase in case 
numbers can be detected in time.
(iii) Local outbreaks require a rapid and rigorous response, including travel 
restrictions, targeted testing, and possibly regional lockdowns, to achieve a rapid 
reduction in prevalence.
3 Develop a longer-term common vision
Develop context-sensitive regional and national action plans as well as European-
level goals, depending on the COVID-19 prevalence. Devise strategies for 
elimination, screening, vaccination, protection of those at high risk, and support for 
those most affected by the COVID-19 pandemic.8
Correspondence
www.thelancet.com   Vol 397   January 9, 2021 93
for Advanced Studies, Vienna, Austria (TC); 
London School of Economics, London, UK (TC); 
University of Trento, Trento, Italy (GG); 
Queen Mary University of London, London, UK 
(DG); London School of Hygiene & Tropical 
Medicine, London, UK (CH); Karolinska Institute, 
Stockholm, Sweden (CH); I-BioStat, Data Science 
Institute, Hasselt University, Hasselt, Belgium 
(NH); Centre for Health Economic Research and 
Modelling Infectious Diseases, Vaccine and 
Infectious Disease Institute, University of Antwerp, 
Antwerp, Belgium (NH); Department of 
Epidemiology, Center for Public Health, Medical 
University of Vienna, Austria (ESc), University 
Medical Center Utrecht, Utrecht, Netherlands (EI, 
MK); Inserm-University Toulouse III Paul Sabatier, 
Toulouse, France (MK-I); Medical University of 
Vienna, Vienna, Austria (PK); Complexity Science 
Hub Vienna, Vienna, Austria (PK); ifo Institute, 
Leibniz Institute for Economic Research at the 
University of Munich, Munich, Germany (AP); 
University of Maribor, Maribor, Slovenia (MP); 
Federico II University of Napoli, Napoli, Italy (FS); 
Centre of Excellence for Particle Physics and 
Cosmology and Danish Institute for Advanced 
Study, University of Southern Denmark, Aarhus, 
Denmark (FS); Campus Institute for Dynamics of 
Biological Networks, Göttingen, Germany (ASc); 
School of Nursing, Psychotherapy and Community 
Health, Dublin City University, Dublin, Ireland 
(ASt); Faculty of Mathematics, Informatics and 
Mechanics, University of Warsaw, Warsaw, 
Poland (ESz)
1 Dorn F, Fuest C, Göttert M, et al. The economic 
costs of the coronavirus shutdown for selected 
European countries: a scenario calculation 
(No. 25). Munich: EconPol Europe, 2020.
2 Kretzschmar ME, Rozhnova G, Bootsma MC, 
van Boven M, van de Wijgert JH, Bonten MJ. 
Impact of delays on effectiveness of contact 
tracing strategies for COVID-19: a modelling 
study. Lancet Public Health 2020; 5: e452–59.
3 Maier BF, Brockmann D. Effective containment 
explains subexponential growth in recent 
confirmed COVID-19 cases in China. Science 
2020; 368: 742–46.
4 Alwan NA, Burgess RA, Ashworth S, et al. 
Scientific consensus on the COVID-19 
pandemic: we need to act now. Lancet 2020; 
396: e71–72.
5 Dehning J, Zierenberg J, Spitzner FP, et al. 
Inferring change points in the spread of 
COVID-19 reveals the effectiveness of 
interventions. Science 2020; 369: eabb9789.
6 Giordano G, Blanchini F, Bruno R, et al. 
Modelling the COVID-19 epidemic and 
implementation of population-wide 
interventions in Italy. Nature Medicine 2020; 
26: 855–60.
7 Haug N, Geyrhofer L, Londei A, et al. 
Ranking the effectiveness of worldwide 
COVID-19 government interventions. 
Nature Human Behavior 2020; 4: 1303–12.
8 Dykstra P, Fortunato E, Grobert N, et al. 
Independent expert report. Improving 
pandemic preparedness and management: 
lessons learned and ways forward. 




november-2020.pdf (accessed Dec 15, 2020).
It is crucial to communicate the 
goal and the advantage of low case 
numbers clearly to foster public 
cooperation. The success of these 
measures depends crucially on the 
cooperation and involvement of 
the public. Making the case for the 
economic and social benefits of 
reducing case numbers will, if clearly 
communicated, greatly foster public 
cooperation.
Controlling COVID-19 will become 
easier. In the near future, increased 
immunisation, more testing, and an 
improved understanding of mitigation 
strategies will further facilitate the 
control of COVID-19.
We urge governments throughout 
Europe to agree on clearly formulated 
common goals, coordinate their 
efforts, develop regionally adapted 
strategies to reach the goals, and 
thereby work resolutely towards low 
case numbers.
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Asymptomatic cases of COVID-19 
are a potential source of substantial 
spread within the community 
setting.1 However, little information 
is available about the infectivity and 
epidemiological significance of people 
with asymptomatic COVID-19.2
Singapore’s testing strategy for 
severe acute respiratory syndrome 
coronavirus 2 is designed to detect 
infection in both symptomatic 
and asymptomatic people. Various 
methods are used. Workers in specific 
industries, such as construction, 
marine, and process industries, are 
routinely tested once per week or every 
two weeks, and all close contacts of 
those who test positive for COVID-19 
are tested as well. All COVID-19 case 
detection, regardless of symptom 
status, triggers public health actions, 
including contact tracing and the 
quarantining of close contacts. A close 
contact generally refers to a person 
who was within 2 m of the index case 
for at least 30 min (or for shorter 
durations in high-risk settings).3 All 
quarantined people are tested by 
PCR at the end of their quarantine 
period, and are only released from 
quarantine when they test negative 
for COVID-19. Serology tests are also 
done in most people who are infected, 
to determine the possible duration of 
their COVID-19 infection, and to assist 
with epidemiological investigations 
and containment efforts.3 As COVID-19 
viral load is typically higher before 
seroconversion than after, seronegative 
cases are thought to be more infectious 
than seropositive cases.4,5
To identify the relative infectivity of 
people with COVID-19 on the basis of 
their symptom and serology status, 
we studied all people who completed 
their quarantine between Aug 1 and 
Oct 11, 2020, as a result of being 
close community contacts of people 
who were infected and who had also 
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